DBV Technologies (NASDAQ:DBVT) Now Covered by StockNews.com

StockNews.com started coverage on shares of DBV Technologies (NASDAQ:DBVT) in a research report report published on Wednesday. The brokerage issued a hold rating on the stock.

DBVT has been the subject of several other reports. JMP Securities restated a “market outperform” rating and set a $5.00 price target on shares of DBV Technologies in a research report on Tuesday, September 24th. HC Wainwright lifted their target price on DBV Technologies from $5.00 to $7.00 and gave the company a “buy” rating in a research report on Thursday, October 24th.

DBV Technologies Stock Performance

Shares of DBVT stock opened at $0.77 on Wednesday. The firm has a market cap of $74.31 million, a P/E ratio of -0.84 and a beta of 0.66. The firm’s 50 day moving average price is $0.75 and its 200-day moving average price is $0.92. DBV Technologies has a one year low of $0.50 and a one year high of $2.14.

Institutional Trading of DBV Technologies

An institutional investor recently raised its position in DBV Technologies stock. Yiheng Capital Management L.P. increased its stake in shares of DBV Technologies S.A. (NASDAQ:DBVT) by 6.2% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,568,909 shares of the company’s stock after purchasing an additional 327,345 shares during the quarter. DBV Technologies accounts for 0.2% of Yiheng Capital Management L.P.’s holdings, making the stock its 15th largest holding. Yiheng Capital Management L.P. owned about 2.89% of DBV Technologies worth $4,172,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 71.74% of the stock is currently owned by hedge funds and other institutional investors.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.